Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Mankind Pharma...

    Mankind Pharma launches hypertension drug at Rs 7.5 per tablet

    Written by Ruby Khatun Khatun Published On 2017-05-18T11:31:31+05:30  |  Updated On 18 May 2017 11:31 AM IST
    Mankind Pharma launches hypertension drug at Rs 7.5 per tablet

    New Delhi: Mankind Pharma said it has launched anti-hypertensive drug Zolahart at an affordable price of Rs 7.50 per tablet.


    Aiming at reducing the most commonly related disease of hypertension, the introduction of Zolahart (Azilsartan) at 51 per cent less price, is done with the mission of achieving the prime objective of – world class quality at most affordable price.


    Azilsartan, a new generation anti-hypertensive drug, offers potent and persistent 24 hours’ blood pressure control. It is proven to be safe for hypertensive patients with comorbid conditions like diabetes or Chronic Kidney Disease (CKD). The recently launched Angiotensin-receptor-blocker (Azilsartan) is the most potent amongst ARBs and is expected to reduce the proportion of patients of uncontrolled BP considerably.


    "At Mankind, we endeavour to bring the latest innovative therapies with assured quality that address primary healthcare challenge in India-world class quality at an affordable price. It is with this thought, we decided to launch Zolahart (Azilsartan), the latest anti-hypertensive drug at the most affordable price of 7.50/Tab," Mankind Group chairman and founder R C Juneja said in a statement.


    The company said the price of its product was 51 per cent lower than that of the other competitor drugs in the segment.

    Angiotensin-receptor-blockeranti-hypertensive drugAzilsartanchronic kidney diseaseCKDhypertension druglaunchesMankind PharmaR C JunejaRs 7.5 per tabletZolahart
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok